Cover
Cover | Jan. 12, 2022 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A supplements Item 9.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2022 related to the completion of the Sale (the "Original Form 8-K"). The purpose of this amendment is to provide certain pro forma financial information in connection with the Sale, and provide additional information with respect to the Company's board of directors (the "Board"). |
Document Period End Date | Jan. 12, 2022 |
Entity File Number | 001-38356 |
Entity Registrant Name | VYNE Therapeutics Inc. |
Entity Central Index Key | 0001566044 |
Entity Tax Identification Number | 45-3757789 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 520 U.S. Highway 22 |
Entity Address, Address Line Two | Suite 204 |
Entity Address, City or Town | Bridgewater |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 08807 |
City Area Code | 800 |
Local Phone Number | 775-7936 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value |
Trading Symbol | VYNE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | true |